top of page

BioLabs Rochester MN Expands Innovation Infrastructure to the Midwest; Names Quantum-Sensing Startup Qtas 2026 Golden Ticket Winner

michelle94735
50 minutes ago
3 min read

November 16, 2026


BioLabs Rochester MN the first Midwest location for BioLabs, the nationally recognized life sciences co-working lab and incubator network, today celebrated the ribbon cutting of its 17,000-square-foot facility with participation from Mayo Clinic, Destination Medical Center (DMC), and the City of Rochester. During the program, BioLabs named German-based Qtas as the recipient of its 2026 Golden Ticket, chosen from a field of 35 applicants, and spotlighted SIME Diagnostics, the facility’s first resident company.



Located on the third floor of Two Discovery Square, BioLabs Rochester MN gives early-stage biotech and health-tech companies turnkey wet lab space, shared equipment, and a collaborative global community, so they can grow without a large upfront investment in lab infrastructure. Over its first five years, the project aims to host 50 companies, bring 100 employees on-site, and attract $40 million in outside funding, advancing Rochester’s position as a global destination for medical innovation and DMC’s vision for the Discovery Square Innovation District.


The program featured remarks from Susan Chase, Chief Business Officer, BioLabs; Patrick Seeb,

Executive Director, DMC; Janani S. Reisenauer, M.D., chair, Thoracic Surgery, and medical director, Research Innovation, Business Development, Mayo Clinic; and Mayor Kim Norton of the City of Rochester.



Today’s event was part of DMC Exchange, Nov. 16–20, a week of events showcasing Rochester’s

progress on health innovation, education, housing, and transit.


Qtas Receives 2026 Golden Ticket

Qtas, a Munich, Germany-based company, received the 2026 BioLabs Rochester MN Golden Ticket, which provides one year of fully paid individual bench space and membership at the fully equipped laboratory.



Qtas has developed a quantum-sensing microscopy approach, which is designed to detect and recover individual rare cells, such as circulating tumor cells, from samples including whole blood or spinal fluid. According to Qtas, recovered cells can then be analyzed at the DNA, RNA, and protein level for potential research applications, including liquid biopsy and cancer research. The Golden Ticket brings an international company to Rochester to build its technology at BioLabs in the Discovery Square Innovation District.


Robin Allert, co-founder and chief executive officer of Qtas, accepted the award on behalf of the company.


The Golden Ticket was designed to accelerate early-stage life science startups working on research and development across a broad range of fields, including oncology, immunology, rare diseases, neuroscience, laboratory automation, and cell, gene, and regenerative therapies.


Resident Spotlight: SIME Diagnostics

SIME Diagnostics, BioLabs Rochester MN’s first resident company, has developed a first-of-its-kind diagnostic platform with multiple applications across acute respiratory care.


Developed in collaboration with leading clinical experts at major U.S. centers of excellence, the platform is reagent free and combines a point-of-care device, single-use cartridge, and AI to measure unique respiratory biomarkers from small volume patient samples, delivering rapid, actionable clinical insights. The technology addresses a critical gap in neonatal and adult intensive care, where rapid biomarker based respiratory diagnostics are not currently available, with the potential to empower clinicians and transform the standard of care.


Its first application targets neonatal respiratory distress syndrome, a critical condition where early identification of surfactant deficiency can fundamentally influence treatment decisions. Nearly 380,000 babies are born prematurely in the U.S. each year, with preterm birth imposing more than $25 billion in annual societal costs. SIME aims to equip clinicians with critical information from birth, enabling earlier, more informed respiratory interventions during the most vulnerable hours of life, when timely intervention can have a profound impact on survival and long-term health outcomes. The neonatal product is currently undergoing final FDA analytical and clinical validation.


Simultaneously, SIME is advancing its platform into adult critical care, with an application for acute respiratory distress syndrome currently being evaluated in a clinical trial at a leading U.S. ICU. Together, these programs demonstrate the potential of a single, scalable technology platform to transform how critical respiratory conditions are identified and managed across critical care settings.


About BioLabs Rochester MN

BioLabs Rochester MN is part of BioLabs, a global innovation infrastructure company creating the

physical and community backbone that powers life science discovery worldwide. Through a growing network of premium shared laboratories and coworking spaces, BioLabs provides turnkey access to state-of-the-art research facilities, entrepreneurial programming, and deep industry and capital connections. These integrated ecosystems enable innovators – from early-stage founders to established R&D teams — to rapidly translate ideas into impact without the constraints of traditional lab ownership. The BioLabs network now spans major innovation hubs across North America, Europe, and Asia, serving as a catalyst for collaboration and a launchpad for breakthroughs that advance human health and sustainability.

 
 

Recent Posts

See All
bottom of page